期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

80岁以上心房颤动患者低强度抗凝治疗的疗效及安全性研究 被引量：1

原文传递
导出
摘要 心房颤动（房颤）是老年人常见的心律失常,随着年龄的增加房颤的发生率逐年增高,其最大的危害为血栓栓塞,尤其是缺血性脑卒中,而华法林是临床上房颤治疗的首选药物[1]。但如何掌握适宜的剂量,在保证其满意疗效的基础上又能使出血的风险尽可能的减少,
作者 卜庆锋 焦殿雷 李法祥
机构地区 中国人民解放军第三七一中心医院老年病科
出处 《实用老年医学》 CAS 2015年第10期874-876,共3页 Practical Geriatrics
关键词 心房颤动患者 低强度抗凝 房颤治疗 缺血性脑卒中 血栓栓塞 安全性评价 永久性房颤 动态心电图 国际标准化比值 出血事件
分类号 R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献8

  • 1Connolly SJ,Pogue J,Yusuf S,et al.Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range[J].Circulation,2008,118(20):2029-2037.
  • 2吴军,郭妍,王俊宏,许迪.不同抗凝强度华法林对80岁及以上心房颤动患者的安全性研究[J].中华老年医学杂志,2011,30(7):540-543. 被引量：12
  • 3Lee BH,Park JS,Park JH,et al.The effect and safety of the antithrombotic therapies in patients with atrial fibrtillation and CHADS2 Score I[J].J Cardiovasc Electrophysiol,2010,21(5):501-507.
  • 4Heeringa J,van der Kuip DA,Hof-man A,et al.Prevalence,incidence and lifetime risk of atrial fibrillatian:the rotterdam study[J].Eur Heart J,2006,27(8):949-953.
  • 5华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82. 被引量：603
  • 6孙艺红,胡大一.华法林对中国人心房颤动患者抗栓的安全性和有效性研究[J].中华内科杂志,2004,43(4):258-260. 被引量：170
  • 7Furusho H,Takamura M,Kaneko S,et al.Current status of anticoagulation therapy for elderly atrial fibrillation patients in Japan[J].Circ J,2008,72(12):2058-2061.
  • 8Kim JH,Song YB,Shin DH,et al.How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?[J].Yonsei Med J,2009,50(1):83-88.

二级参考文献39

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量：162
  • 2Connolly SJ,Pogue J,Yusuf S, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation, 2008,118 : 2029-2037.
  • 3Lee BH, Park JS, Park JH, et al. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS2 Score 1. J Cardiovasc Electrophysiol, 2010,21 ; 501-507.
  • 4Heeringa J,Van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the rotterdam study. Eur Heart J , 2006, 27: 949-953.
  • 5Steger C, Pratter A, Martinek BM, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke Registry. Eur Heart J, 2004, 25:1734-1740.
  • 6Fihn MD,Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med, 1996, 124: 970-979.
  • 7Copland M, Walker ID, Tait RC. Oral anticoagulation and haemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med,2001, 161: 2125-2158.
  • 8Johnson CE, Lira WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major haemorrhage and stroke in more than 500 patient-years of follow-up. JAGS, 2005, 53.. 655-659.
  • 9Pengol V, Cuechinil U, Ilieetol S. Lower versus standard intensity oral anticoagulant therapy(OAT) in elderly warfarin-experieneed patients with non-valvular atrial fibrillation. Thromb Haemost, 2010, 103: 442-449.
  • 10Furusho H, Takamura M, Kaneko S, et al. Current status of antieoagulafion therapy for elderly atrial fibrillation patients in Japan. Circ J, 2008, 72: 2058-2061.

共引文献777

同被引文献13

引证文献1

二级引证文献11

实用老年医学
2015年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部